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Abstract Transketolase (TK) reactions play a crucial role in
tumor cell nucleic acid ribose synthesis utilizing glucose carbons,
yet, current cancer treatments do not target this central pathway.
Experimentally, a dramatic decrease in tumor cell proliferation
after the administration of the TK inhibitor oxythiamine (OT)
was observed in several in vitro and in vivo tumor models. Here,
we demonstrate that pentose cycle (PC) inhibitors, OT and
dehydroepiandrosterone (DHEA), efficiently regulate the cell
cycle and tumor proliferation processes. Increasing doses of OT
or DHEA were administered by daily intraperitoneal injections
to Ehrlich’s ascites tumor hosting mice for 4 days. The tumor cell
number and their cycle phase distribution profile were determined
by DNA flow histograms. Tumors showed a dose dependent
increase in their G0-G1 cell populations after both OT and
DHEA treatment and a simultaneous decrease in cells advancing
to the S and G2-M cell cycle phases. This effect of PC inhibitors
was significant, OT was more effective than DHEA, both drugs
acted synergistically in combination and no signs of direct cell or
host toxicity were observed. Direct inhibition of PC reactions
causes a G1 cell cycle arrest similar to that of 2-deoxyglucose
treatment. However, no interference with cell energy production
and cell toxicity is observed. PC inhibitors, specifically ones
targeting TK, introduce a new target site for the development of
future cancer therapies to inhibit glucose utilizing pathways
selectively for nucleic acid production.
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1. Introduction
Increased metabolism of glucose in malignant tissue is the
most characteristic sign of the severe metabolic imbalance
between tumor cells and their surrounding tissue [1]. This
phenomenon utilizing the 18£uoro-deoxyglucose tracer mole-
cule, detected by positron emission tomography, has become a
reliable technique for detecting and classifying tumors. This
technique has been useful in detecting human malignancies [2]
based on the common characteristics that malignant tumors
accumulate glucose about 8.5^15 times more intensively than
their surrounding normal tissue marked by their increased
di¡erential glucose uptake ratio.
It is broadly contemplated that glucose carbons intensively
accumulate in cancer cells because of increased energy re-
quirements and nucleic acid synthesis and that labelling glu-
cose carbons is a useful diagnostic tracer in cancer. Recent
new reports also indicate that increased glucose uptake in
malignant tumors will become utilized in the treatment of
cancer using 2-deoxyglucose [3]. Interestingly, 2-deoxyglucose,
a false substrate of glycolysis and the pentose cycle (PC),
induced a signi¢cant G1 cell cycle arrest in leukemia cells
and decreased the percentage of cells in S and G2-M phases.
Introduction of apoptosis by combined treatment with re-
combinant human TNF-K and 2-deoxyglucose has also been
achieved in the same model [4]. However, false glucose metab-
olites such as deoxyglucose fall short of acting selectively on
intracellular anabolic reactions by strongly in£uencing intra-
cellular energy production and basic cell functions other than
the cell division process. This signi¢cant disadvantage using
deoxyglucose is yet to be overcome that a¡ects not only tu-
mors but also all high glucose utilizing tissues such as the
brain and testis.
Studies utilizing isotopically labelled glucose carbons recov-
ered from tumor cell RNA and DNA have revealed that glu-
cose carbons are also the main source of de novo lipid [5] and
nucleic acid synthesis [6,7] besides their central role in energy
production. Therefore, glucose utilizing intracellular anabolic
pathways in the PC o¡ers a new approach to tumor therapy
[8]. Since the proliferation process is governed by the replica-
tion of DNA in the S cell cycle phase known as the ‘S peak’ in
malignant tumors, the intensive non-oxidative synthesis of
ribose by transketolase (TK) [6,7] during this process is a
promising new target site for cancer treatment protocols.
The recently observed high label loss (s 35%) on the sixth
(C6) carbon of glucose recovered from DNA after culturing
H9 (T-cell) and Hep G2 tumor cells for 53 days in the pres-
ence of 100% C6-labelled glucose, again, underlines the crit-
ical role of TK and the non-oxidative synthesis of ribose in
the tumor proliferation process [9]. The clinical signi¢cance of
these studies is evidenced by the fact that TK reactions are
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currently promoted by the uncontrolled administration of thi-
amine, the co-factor of this central enzyme reaction in tumor
cell proliferation, to cancer patients through total parenteral
nutrition, special diets, vitamin supplements and food prod-
ucts [10,11].
Here, we demonstrate that the inhibitory e¡ect of the PC
inhibitor drugs, oxythiamine (OT) and dehydroepiandroster-
one (DHEA) [12], on tumor cell proliferation is associated
with a cell cycle arrest in the G1 phase. We also demonstrate
that this e¡ect of PC inhibitor drugs on the cell cycle is similar
to that of deoxyglucose and that on signs of apoptosis, direct
cell or host toxicity is present.
2. Materials and methods
2.1. Chemicals
OT, DHEA sulfate, Hoechst 33342, (propidium iodide (PI)), phos-
phate, citric acid, Dulbecco’s phosphate-bu¡ered saline, dimethyl sulf-
oxide (DMSO) and L-leucyl-methylester were purchased from Sigma.
RNAse was purchased from Boehringer and Immuno Floure Mount-
ing Medium was purchased from ICN.
2.2. Animals and tumor cells
Ehrlich’s ascites tumor cells were maintained in the abdomen of
12 weeks old 25^30 g C57BL/65 mice and weekly transplanted by
intraperitoneal (i.p.) aspiration and inoculation. The animals were
housed in a climate-controlled pathogen-limited environment with
standard rodent food and water ad libitum. Animals before tumor
implantation were selected using a random number chart without
regard to treatment group assignment. 20U106 tumor cells/mouse
(100 Wl) were i.p. injected in each experimental animal. Tumor cell
viability was checked after each harvesting and before each inocula-
tion by the trypan blue exclusion test. All preparations were highly
viable (s 95%). Animal studies were conducted according to guide-
lines accepted by the University Animal Care and Use Committee.
Animal experiments were repeated twice, unless speci¢ed otherwise in
the text.
In vivo drug treatment. 4 Days after tumor implantation when cell
growth was ensured by increase of weight, the mice were divided into
DHEA-, OT- or combined DHEA-OT-treated and control (n = 6)
groups. A 500 mg/ml solution of DHEA was prepared in 60%
DMSO-Dulbecco’s phosphate-bu¡ered saline mixture and 500 mg/
ml OT solution was prepared in Dulbecco’s phosphate-bu¡ered saline
and diluted to the required concentrations as in Fig. 1. The separate
drug solutions or a combination of both were administrated i.p. for
4 days. Control animals received the maximum concentration of
DMSO-Dulbecco’s phosphate-bu¡ered saline mixture vehicle for the
same length of time as the treated groups. The body weight, food and
water intake as well as the physical activity of animals were daily
registered. Cells were aspirated and the tumor volume measured using
a calibrated syringe. Cell cycle phase distribution, cell viability and
apoptosis were measured by £ow cytometry and £uorescent micros-
copy.
2.3. Histology
The animals were killed by dislocation and the liver, kidney and
heart were excised, washed and cut into pieces which were ¢xed in
10% neutral phosphate-bu¡ered formalin, embedded in para⁄n. The
para⁄n blocks were sectioned at 5 microns and stained with H and E
for histopathological evaluation. All tissues were evaluated histologi-
cally.
2.4. Flow cytometry
2.4.1. Flow cytometry experiments. Flow cytometry experiments
were carried out using an Epics ELITE and an Epics XL £ow cytom-
eter (Coulter Corporation, Hialeah, FL, USA). Excitation of the tu-
mor cell samples was performed using the 488 nm air-cooled argon
ion laser operating at 15 mW. Forward scatter (FSC), side scatter
(SSC) and red £uorescence (695 nm) for PI were acquired. Optical
alignment was achieved by the optimized signal from 10 nm £uores-
cent beads using standard procedures recommended by the vendor
(Immunocheck, Epics Division). An increased length of time and ex-
tended acquisition were used to control the stability of DNA histo-
grams. Aggregates were excluded by gating single cells using their area
versus peak £uorescent signal.
2.4.2. Cell cycle phase determination. Fresh tumor cells were di-
luted in phosphate citrate bu¡er containing 0.2 M Na2HPO4 and
0.1 M citric acid (24:1, pH 7.8). Tumor samples were incubated for
1 h with 5 mM L-leucyl-methylester at 37‡C in order to eliminate
macrophages from the samples. Cells were stained with 5 Wg/ml
Hoechst 33342 and analyzed after 30 min at room temperature in
the dark. The cell cycle phase distribution pro¢le of tumors was de-
termined by DNA £ow histograms of the various cell cycle phases
(G1-G0, S, G2-M). Di¡erent areas of the DNA histograms were an-
alyzed assuming the Gaussian function of the G1 and G2-M peaks
and attributing the remaining part of the DNA histogram to cells in
the S phase [13,14]. All DNA histograms were collected in three sep-
arate loadings and we accepted measurements when the di¡erence was
less than 8% between measurements. DNA analysis (ploidy analysis)
on single £uorescence histograms was performed using the Multicycle
software (Phoenix Flow Systems, San Diego, CA, USA). Cell viability
was estimated after 18 Wg/ml PI incubation. The argon ion laser ad-
justed to 15 mW at 488 nm induced sample excitation.
2.4.3. Assessment of apoptosis. Three methods were used in order
to check whether OT or DHEA induce apoptosis in Ehrlich’s tumor
cells of treated mice. As a positive control, vincristine, a common
anti-cancer drug which has been described to induce apoptosis [15],
was administrated at a single dose of 5 mg/kg [16] to mice hosting
Ehrlich ascites tumor cells and in the same conditions.
2.4.3.1. Assessment of apoptosis by £ow cytometry. Samples were
prepared as described above under determination of cell cycle phases.
Hoechst 33342 was excited under 333^364 nm wavelengths, 25 mW
and £uorescence was collected using 675 and 395 nm band-pass ¢lters
[13^17].
2.4.3.2. Assessment of apoptosis by £uorescent microscopy. Quan-
ti¢cation of condensed chromatin was carried out on the same sam-
ples used for viability and cell cycle distribution studies which were
already stained with PI and Hoechst 3342, respectively. After centri-
fugation for 7 min at 40Ug at room temperature, 12 Wl of Immuno
Floure Mounting Medium was added to the pellets. Cells were inves-
tigated under a Zeiss Axioskop epi£uorescence microscope. Pycnotic
cells with condensed nuclei and/or shrunken cytoplasm were counted
using standard methods.
2.4.3.3. Assessment of apoptosis by a pulse method. Tumor cells
were suspended in phosphate citrate bu¡er and incubated with
5 mM of L-leucyl-methylester during 1 h at 37‡C. Cells were stained
with 5 Wg/ml Hoechst 33342 for 15 s and then analyzed by £ow
cytometry. Apoptotic cells were identi¢ed by their lessened forward
light scattering and increased side light scattering [18,19].
2.5. Statistical analysis
Statistical analysis was performed by using the parametric unpaired,
two-tailed independent sample t test with 95% con¢dence intervals
(W= 2.58) and P6 0.05 was considered to indicate signi¢cant di¡er-
ence between treated and control groups.
3. Results
3.1. In vivo e¡ect of DHEA and OT treatment on tumor cell
growth, the cell cycle and cell death
11 Groups of mice (n = 6, each) were used to determine the
dose dependent e¡ect of DHEA and OT on the growth of the
Ehrlich’s ascites tumor. Increasing doses from 100 to 500 mg/
kg of both DHEA and OT were injected daily during 4 days.
The weight of treated tumor bearing mice increased less dur-
ing the treatment than the weight of the untreated control
(control, 33.9^43.86 g; OT, 33.4^35.7 g; DHEA, 32.06^
37.2 g). Fig. 1 show that both DHEA and OT decrease
both the cell volume and cell number of the tumor comparing
to the control. OT inhibited tumor growth by 43% at a dose
of 300 mg/kg mice/day. This inhibition was further increased
to 84% at a dose of 500 mg/kg mice/day. Whereas DHEA
inhibition of tumor growth was 50% at 100 mg/kg mice, a
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higher DHEA concentration did not further induce any ben-
e¢c change. Flow cytometry measurement showed that un-
treated control tumor cells preserved 98% viability which
was maintained (over 95%) in tumor cells from all treatments.
These results indicated that the inhibition of the PPP through
its non-oxidative phase (with OT) is much more e¡ective in
decreasing tumor cell proliferation than the inhibition of PPP
through its oxidative phase (with DHEA).
To examine the e¡ects of the PPP inhibitors on cell cycle
distribution, we subjected fresh tumor cells from mice treated
4 days with 0, 100, 200, 300, 400 and 500 mg/kg of DHEA or
OT to £ow cytometry analysis of the total DNA content. Fig.
2A and B shows, in percentage of cells, the distribution of cell
cycle phases. The percentage of cells in G0-G1 phase in-
creased about 1.5-fold in cells from mice treated with the
higher doses of DHEA or OT, whereas the percentage of cells
in both S and G2 phases decreased. A dose dependent G1
arrest and S and G2 decrease were observed in the range of
0^400 mg/kg of DHEA or OT. A good correlation exists
between this dose dependent G1 arrest and the inhibition of
tumor growth (Fig. 1).
Apoptosis was assessed during the £ow cytometric cell cycle
determination as described by Belloc et al. [13]. Fluorescence
emission at 395 and 675 nm in control mice and both OT- and
DHEA-treated mice indicates no sign of cell death. Cells from
treatment with high doses of these drugs were also analyzed
for apoptosis using epi£uorescence microscopy. Results from
these two methods were in general agreement, showing no
apoptosis. These methods were validated using cells from vin-
cristine-treated mice as a positive control. Apoptosis of Ehr-
lich ascites tumor cells was induced by the administration of a
single dose of 5 mg/kg of vincristine to the mice hosts [14].
The laser-beam £ow cytometric analysis of tumor cells from
vincristine-treated mice displayed a population of cells with
decreased £uorescence emission at 395 nm and increased at
695 nm. The combination of both high £uorescence emission
at 395 nm and low at 695 nm is an indication of apoptotic
cells [18,19]. This population of apoptotic cells was absent in
cells from untreated mice.
3.2. E¡ects of combined treatment with DHEA and OT on
tumor cell growth in vivo
In order to evaluate the e¡ect of inhibiting simultaneously
oxidative (G6PDH) and non-oxidative (TK) pentose phos-
phate pathways, we have administrated to mice a combination
of OT and DHEA at several concentrations. The mixtures of
OT and DHEA were injected to groups of six mice each. Since
the maximum tumor inhibitory e¡ect was reached at a rela-
tively low dose of DHEA, the dose of DHEA was ¢xed at 300
mg/kg and OT doses were variable from 200 to 500 mg/kg. A
mixture of OT and DHEA at high doses (500 and 400 mg/kg,
respectively) was also tested. Table 1 compares the e¡ects of
di¡erent treatments with OT and DHEA combinations on
tumor cell proliferation expressed as percentage growth inhib-
ition. When OT and DHEA were administered separately, for
example OT at 400 mg/kg and DHEA at 300 mg/kg, inhib-
ition as measured by the total cell number was reduced by
46.3 and 45.3%, respectively. The reduction or inhibition in-
creased to 86.41% when treatments with drugs at these doses
were combined. Similar di¡erences on tumor growth inhibi-
tion between separate versus combined treatment with OT
and DHEA were observed at other doses of these drugs
used. The maximum e¡ect was achieved at the highest con-
centrations of OT and DHEA administrated simultaneously
Fig. 1. Dose dependent e¡ect on Ehrlich ascites tumor cell prolifera-
tion after 4 days treatment with several doses of A: OT, B: DHEA
and combined doses of OT and DHEA. The number of cells after
OT, DHEA and combined doses of OT and DHEA treatment are
expressed as a percentage of control (100%) cell proliferation (total
cell number).
Table 1
Growth inhibition e¡ect of combined OT and DHEA treatment at several doses
Number of mixture OT (mg/kg/day) DHEA (mg/kg/day) Growth inhibition (%)
1 300 200 50.2
2 200 300 49.8
3 300 300 69.61
4 400 300 86.4
5 500 300 86.12
6 500 400 94.3
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(500 and 400 mg/kg/day for OT and DHEA, respectively).
These results show that OT and DHEA are more e¡ective
in inhibiting tumor growth when used in combination than
used separately and that an inhibition of tumor cell growth of
around 94% is achievable at the highest dose of OT and
DHEA used. Fig. 2C shows the changes in distribution (in
percentage) of cells in di¡erent cell cycle phases after di¡erent
combined DHEA and OT treatments. These results indicate
that all mixtures induce an arrest of the cycle at the G1 phase,
thus reducing the cell population in the G2 phase comparing
to control.
3.3. Direct toxic e¡ect
In order to evaluate any possible direct toxic e¡ect due to
the high daily repetitive administration of drugs, we treated
eight groups of mice (n = 6) in the following way. These were
¢rst divided into four groups of mice receiving tumor implants
and the other four groups serving as healthy control. Mice in
each group of the four were either given OT 300 mg/kg,
DHEA 200 mg/kg, a mixture of OT 300 and DHEA 200 or
vehicle control. Half of the tumor bearing animals were killed
and the tumor volume and cell number were registered after
4 days treatment. Since these animals seemed to tolerate these
doses of OT and DHEA, we decided to continue the daily
injecting for an additional 10 days. The health and weight of
the animals were monitored by daily inspections and body
weight measurement. All animals were killed after 2 weeks.
We found that the percentage of tumor growth inhibition was
maintained during the prolonged treatment. The healthy con-
trol animals receiving the same doses of drugs showed no
change in their behavior or weight after 2 weeks of treatment.
3.4. Histotoxicity
The histotoxicity of DHEA, OT and their mixture was
checked on some vital tissue as liver, heart and kidney of
the mice hosting Ehrlich’s tumor and which were treated
with a doses of 300 mg/kg/day DHEA or 400 mg/kg/day
OT or a mixture of both. No signs of toxicity were observed
in all these tissue as compared to the controls.
4. Discussion
Cell cycle phase distribution determinations by £ow cytom-
etry are widely used for the characterization of anti-cancer
properties of tumor inhibitory drugs and their e¡ect on cell
proliferation. The fundamental task is to measure cell popu-
lations with single DNA (G0-G1), which are replicated during
the S phase followed by the progression towards a completed
cell division through the G2-M phase [18,19]. Oncogenic proc-
esses exert their greatest e¡ect by targeting particular regula-
tors of the G1 phase [20,21]. During preparation in the G1
phase for DNA replication, cells respond to extracellular sig-
nals by either advancing towards a division or withdrawing
from the cycle into a resting state (G0) [22,23]. Malignant
tumors are characterized by an increase in their cell popula-
tions exhibiting S (s 10%) and G2-M (s 20%) phases while
cells in their G0-G1 (6 70%) phases are signi¢cantly less fre-
quent than in normal tissue (G0-G1s 90%, S6 3%, G2-
M6 5%). Therefore, a G1 arrest of tumor cells in cancer ther-
apy is a rational and signi¢cant goal to achieve.
Flow cytometry is also useful for simultaneous cell cycle
analysis and apoptosis detection by FSC and SSC determina-
Fig. 2. Cell cycle phase distribution in Ehrlich’s tumors after OT
treatment. Black bars represent treated control tumor cell cycle fre-
quency distribution (Y axis) as percentage sorting into the G0-G1, S
and G2-M phases. Empty bars represent 100, 200, 300 and 400 mg/
kg/day drug treatment in the same order. (A) Increasing doses of
OT increased cell populations exhibiting G0-G1 cycle phases while
inhibiting both the S and G2-M cycles occured after in vivo treat-
ment (n = 6, values represent mean+S.D., * means signi¢cantly dif-
ferent P6 0.05, **P6 0.01). (B) Increasing doses of DHEA in-
creased cell populations exhibiting G0-G1 cycle phases while
inhibiting both the S and G2-M cycles, although this e¡ect of
DHEA was less prominent and not as rapid as after OT treatment
(n = 6, mean+S.D., *P6 0.05, **P6 0.01). (C) Empty bars represent
200, 300, 400 and 500 mg/kg/day of OT dose in the same order.
The combined treatment resulted in a rapid and signi¢cant change
in the cell cycle distribution pro¢le, especially a¡ecting the G2-M
phase of tumors and this e¡ect was additive at all doses. The high-
est dose of combined treatment practically eliminated the G2-M
phase (90.2%). (n = 6, mean+S.D., *P6 0.05, **P6 0.01).
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tions. Our histopathological data indicate no toxic e¡ect of
the PC inhibitor drugs on the liver, heart and kidney of the
animals treated, while exerting a strong regulatory e¡ect on
the cell cycle of the tumor cells consistent with an arrest in the
G1 phase. The health of the animals was not a¡ected by
prolonged (2 weeks) treatments with the maximum dose of
either drug as indicated by invariable daily food consumption,
water intake, daily activity, weight gain and the lack of dis-
comfort or distress.
In the present study, we demonstrated that inhibitors of the
oxidative and non-oxidative pentose phosphate pathway reac-
tions regulate the cell division process and induce a G1 arrest
in Ehrlich’s ascites tumor cells in mice. Moreover, this e¡ect
was dependent on the dose of PC inhibitor drugs given and
the two drugs acted synergistically when administered in com-
bination. Both drugs, OT and DHEA, have been described to
inhibit cell growth in the Ehrlich ascites tumor model [7] and
here, we present new data that these drugs a¡ect tumor cells
by causing an arrest in the G1 phase which was more pro-
nounced after treatment with OT. The strong e¡ect of OT on
the regulation of the cell cycle, either alone or in combination
with DHEA, has not previously been reported in the medical
literature.
One important feature of the resting cell is the limited ca-
pacity to synthesize nucleotides. The G1 arrest observed after
treatment with inhibitors of the non-oxidative and oxidative
steps of the PC is consistent with their central regulating role
in the synthesis of pentose phosphates from glucose and the
production of backbone molecules necessary to synthesize nu-
cleic acids de novo or through the salvage pathways of nu-
cleotide bases. The direct inhibition of such a central process
is a strong limiting factor for tumor cells to enter the S phase
and complete a mitosis. Inhibition of the non-oxidative steps,
selectively by OT, is critical for limiting pentose phosphate
synthesis since this reaction produces over 70% of the ribose
moiety in nucleic acids of cultured or in vivo hosted tumor
cells [6,7,9].
Growth factors in£uence the same pentose cycle pathways,
yet, their e¡ect is the opposite to that of PC inhibitors. For
example, in vivo administration of the platelet derived growth
factor resulted in a signi¢cant increase in the levels of PC
metabolites in rat liver as early as 5 min after injection [24].
The intracellular levels of PC metabolites, especially that of
xylulose-5P which is a central metabolite of the non-oxidative
pathway, act as signal molecules in the recruitment of glucose
carbons [25] into the cell and regulate cell cycle progression by
the expansion of the PC metabolite pool observed in tumor
cells [26]. It is very likely that the necessary levels of PC
metabolites to enter the S cell cycle phase through ‘metabolic
priming’ are not achieved after treatments with PC inhibitor
drugs which induce a withdrawal from the cycle as observed
in our studies.
The absence of apoptotic cell death, observed after OT or
DHEA treatment directly on tumor cells while strongly regu-
lating the cell cycle, can be explained by the fact that these
drugs a¡ect central and speci¢c glucose utilizing metabolic
pathways which are involved in nucleic acid synthesis proc-
esses while having little e¡ect on glycolysis and intracellular
energy production. Tissues exhibiting slow proliferation rates
are highly resistant to such treatments due to the low de novo
synthesis and high recycling rate of nucleotides.
Bene¢ts from the application of PC inhibitor drugs in the
treatment of cancer would also include the ‘synchronization’
of cancer cells in the G1 cell cycle phase to increase the e⁄-
cacy of G1 speci¢c anti-cancer drugs such as 6-mercaptopurin,
thioguanin, prednisolone and tyrphostins [27,28]. PC inhibi-
tors may increase the e¡ect of anti-cancer drugs and allow for
a decrease in their toxic doses given in advanced chemother-
apy resistant cases of cancer.
In summary, non-oxidative PC reactions o¡er a new target
site for cancer treatment with a strong regulatory e¡ect on the
cell cycle. PC inhibitors in a combined treatment o¡er a new
treatment modality in malignancies with emphasis on arrest-
ing tumor cell growth instead of killing tumor cells at any
expense. This is achieved by taking advantage of the strong
subservience of tumor cells on glucose carbons, which are
directed toward the synthesis of nucleic acid while other glu-
cose utilizing pathways are not a¡ected.
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